VIGL — Vigil Neuroscience Balance Sheet
0.000.00%
Last trade - 00:00
- $101.85m
- -$16.09m
- 23
- 35
- 17
- 14
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Cash and Equivalents | ||||
Short Term Investments | ||||
Cash and Short Term Investments | 24.2 | 91.4 | 187 | 118 |
Prepaid Expenses | ||||
Total Current Assets | 25.3 | 97.5 | 198 | 122 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | 0 | 1.27 | 1.4 | 17.9 |
Other Long Term Assets | ||||
Total Assets | 25.3 | 102 | 200 | 141 |
Accounts Payable | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Current Portion of Long Term Debt / Capital Leases | ||||
Total Current Liabilities | 2 | 9.88 | 11.3 | 11.7 |
Capital Lease Obligations | ||||
Total Long Term Debt | ||||
Total Debt | ||||
Total Other Liabilities | ||||
Total Liabilities | 6.54 | 9.95 | 11.3 | 24.6 |
Redeemable Preferred Stock | ||||
Non Redeemable Preferred Stock | ||||
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
Other Equity | ||||
Total Equity | 18.8 | 92.5 | 189 | 116 |
Total Liabilities & Shareholders' Equity | 25.3 | 102 | 200 | 141 |
Total Common Shares Outstanding |